- Home
- VTYX vs BMEA Comparison
VTYX vs BMEA Comparison
Compare VTYX & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- BMEA
- Stock Information
- Founded
- VTYX 2018
- BMEA 2017
- Country
- VTYX United States
- BMEA United States
- Employees
- VTYX N/A
- BMEA N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- VTYX Health Care
- BMEA Health Care
- Exchange
- VTYX Nasdaq
- BMEA Nasdaq
- Market Cap
- VTYX 154.9M
- BMEA 145.0M
- IPO Year
- VTYX 2021
- BMEA 2021
- Fundamental
- Price
- VTYX $2.08
- BMEA $4.25
- Analyst Decision
- VTYX Buy
- BMEA Buy
- Analyst Count
- VTYX 4
- BMEA 13
- Target Price
- VTYX $11.33
- BMEA $27.92
- AVG Volume (30 Days)
- VTYX 1.9M
- BMEA 831.0K
- Earning Date
- VTYX 02-25-2025
- BMEA 10-29-2024
- Dividend Yield
- VTYX N/A
- BMEA N/A
- EPS Growth
- VTYX N/A
- BMEA N/A
- EPS
- VTYX N/A
- BMEA N/A
- Revenue
- VTYX N/A
- BMEA N/A
- Revenue This Year
- VTYX N/A
- BMEA N/A
- Revenue Next Year
- VTYX N/A
- BMEA N/A
- P/E Ratio
- VTYX N/A
- BMEA N/A
- Revenue Growth
- VTYX N/A
- BMEA N/A
- 52 Week Low
- VTYX $1.67
- BMEA $3.61
- 52 Week High
- VTYX $11.48
- BMEA $20.21
- Technical
- Relative Strength Index (RSI)
- VTYX 45.64
- BMEA 42.32
- Support Level
- VTYX $1.83
- BMEA $3.78
- Resistance Level
- VTYX $2.61
- BMEA $4.29
- Average True Range (ATR)
- VTYX 0.18
- BMEA 0.30
- MACD
- VTYX -0.03
- BMEA 0.15
- Stochastic Oscillator
- VTYX 32.26
- BMEA 89.71
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.